Real-World Outcomes in Relapsed/Refractory Multiple Myeloma Patients Treated, or Eligible for Treatment, With Idecabtagene Vicleucel
Clinical trial NCT06154902 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06154902
- Sponsor
- Bristol-Myers Squibb
- Status
- ACTIVE_NOT_RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2022-07-29
- Primary completion
- 2027-07-31
- Enrollment
- 350
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.